HIV vaccine candidate moves to human safety tests
NCT ID NCT04177355
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 1 trial tested an experimental HIV vaccine in 127 healthy, HIV-uninfected adults. The vaccine uses a protein called BG505 SOSIP.664 gp140 combined with various adjuvants to boost immune response. The main goal was to check safety and how well the vaccine triggers an immune reaction. Results will help decide if further testing is warranted.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HIV-1 BG505 SOSIP.664 gp140 vaccine with adjuvants (TLR agonist, alum, 3M-052-AF, CpG 1018, GLA-LSQ, Trimer 4571)
What this could lead to
If successful, this could point toward a safe and effective HIV vaccine that prevents infection.
What could go wrong
This is an early Phase 1 trial focused on safety and immune response, not on preventing HIV. The vaccine may not produce strong enough immunity or could have side effects. Many HIV vaccine candidates have failed in later stages.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alabama CRS
Birmingham, Alabama, 35294, United States
-
Brigham and Women's Hospital Vaccine CRS (BWH VCRS)
Boston, Massachusetts, 02115-6110, United States
-
Columbia P&S CRS
New York, New York, 10032, United States
-
New York Blood Center CRS (Site 31801)
New York, New York, 10065, United States
-
Penn Prevention CRS
Philadelphia, Pennsylvania, 19104, United States
-
Seattle Vaccine and Prevention CRS
Seattle, Washington, 98109-1024, United States
-
The Hope Clinic of the Emory Vaccine Center CRS
Decatur, Georgia, 30030, United States
-
The Ponce de Leon Center CRS
Atlanta, Georgia, 30308-2012, United States
-
University of Pittsburgh CRS
Pittsburgh, Pennsylvania, 15213, United States
-
University of Rochester Vaccines to Prevent HIV Infection CRS
Rochester, New York, 14642, United States